VANCOUVER, British Columbia, February 22, 2019
Lungpacer Medical, Inc., a medical device company developing an intravenous catheter-based phrenic-nerve-pacing system, announced today that the FDA has approved the IDE to begin the RESCUE 3 randomized clinical study. This study is designed to evaluate whether Lungpacer therapy improves inspiratory muscle strength and weaning success in subjects who have failed to wean from mechanical ventilation. The study will enroll subjects from the US, Europe and other Tier 1 countries, to evaluate the safety and effectiveness of the Lungpacer technology. Additional information can be found at ClinicalTrials.gov, NCT03783884.
